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:KDW¶VDOUHDG\NQRZQDERXWWKLVWRSLF" 
x Verrucae are notoriously difficult to treat, can last for many years, and cause 
pain and discomfort.  
x There is a lack of high quality evidence evaluating verrucae treatments and 
considerable uncertainty regarding optimal treatments.  
x Current common treatments of choice are salicylic acid and cryotherapy; 
however, although both treatments are equally effective, the clearance rate for 
these treatments is low (14%). 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
What does this study add? 
x This trial evaluated the clinical and cost effectiveness of a needling technique, 
relative to callus debridement.  
x There are two published studies on this treatment: a retrospective case series 
evaluation and a small randomised controlled trial which reports needling to 
be more effective than cryotherapy.  
x This trial found no evidence to suggest that needling increases verrucae 
clearance rates. 
x This trial provides evidence that needling significantly reduces pain compared 
to callus debridement. 
 
ABSTRACT 
Background: Verrucae are a common foot skin pathology which can in some cases 
persist for many years. Plantar verrucae can be unsightly and painful. There are a 
range of treatment options including needling.  
Objectives: The EVerT2 trial aimed to evaluate the clinical and cost effectiveness of 
the needling procedure for the treatment of plantar verrucae, relative to callus 
debridement.  
Methods: This single centre randomised controlled trial recruited 60 participants 
(aged 18 years and over with a plantar verruca).  Participants were randomised 1:1 
to the intervention group (needling) or the control group (debridement of the 
overlying callus). The primary outcome was clearance of the index verruca at 12 
weeks after randomisation. Secondary outcomes include recurrence of the verruca; 
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clearance of all verrucae; number of verrucae; size of the index verruca; pain; and 
participant satisfaction at 12 and 24 weeks. A cost-effectiveness analysis was 
carried out from the NHS perspective over 12 weeks.   
Results: Sixty eligible patients were randomised (needling group n=29, 48.3%; 
debridement group n=31, 51.7%) and 53 were included in the primary analysis 
(needling n=28, 96.6%; debridement n=25, 80.7%).  Clearance of the index verruca 
occurred in 8 (15.1%) participants (needling n=4, 14.3%; debridement n=4, 16.0%, 
p=0.86).  The needling intervention costs were on average £14.33 (95% CI 5.32 to 
23.35) more per patient than debridement.  
Conclusions: There is no evidence that the needling technique is more clinically or 
cost effective than callus debridement. The results show a significant improvement in 
pain outcomes after needling compared to the debridement treatment alone.  
 
Trial registration number: Current Controlled Trials ISRCTN16429440  
 
INTRODUCTION 
Plantar verrucae (or warts) are common, with prevalence rates estimated between   
0.84% (USA)1 and 12.9% (Russia).2 A Cochrane systematic review of 21 trials for 
wart treatments with placebo groups3 reported clearance rates that averaged 27% 
(range 0% to 73%) in the placebo groups after an average period of 15 weeks (range 
4 to 24).  Whilst these data have led some practitioners to recommend that warts 
should not be treated at all,4,5 patients often still seek treatment if verrucae are 
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unsightly or painful. There is uncertainty around the optimal treatment of verrucae 
and a need for high quality trials to evaluate therapies.  
The Falknor needling technique6, first described in the 1960s, and has recently 
received renewed interest as a treatment, involves administering a local anaesthetic 
and repeatedly inserting a needle into the verruca until it enters the underlying 
dermis and subcutaneous fat layer.  The mechanical trauma to the viral tissue is 
believed to evoke inflammation and hence enhance the immune response in the 
area.7 In a retrospective review of 45 patients who received needling, thirty-one 
(69%) experienced clearance of verrucae, three (7%) demonstrated a reduction in 
size and pain, and 11 (24%) showed no improvement eight weeks after treatment.8  
To our knowledge, there is only one published randomised controlled trial (RCT) 
evaluating the effectiveness of the needling procedure.9 This trial randomised 37 
participants to receive either needling or cryotherapy. There was a statistically 
significant reduction in clearance of the primary verruca 12 weeks after the initial 
treatment (needling 64.7% (11/17), cryotherapy 6.2% (1/16); S (? 
The objective of the EVerT2 (Effective Verruca Treatments 2) trial was to evaluate 
the clinical and cost effectiveness of the needling procedure compared with callus 
debridement for the treatment of plantar verrucae.  
PATIENTS AND METHODS 
Trial design  
Full details are published elsewhere10 and are provided in brief below.  This was a 
single centre, pragmatic, open, two-armed RCT with an economic evaluation. Ethical 
approval was obtained from the University of Salford, Department of Health Sciences 
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Ethical Approval Committee (HSCR15/24), and the University of York, Department of 
Health Sciences Research Governance Committee (HSRGC/2014/98/B). 
 
Study population 
Patients were eligible if they were aged 18 years or over and had a plantar verruca 
on weight bearing skin that, in the opinion of the podiatrist, was suitable for both 
treatments. Potential participants were excluded if they: were unsuitable for local 
anaesthesia; had impaired healing; were immunosuppressed (or taking 
immunosuppressant drugs); had peripheral neuropathy or renal failure requiring 
dialysis; or were pregnant, unable or unwilling to give informed consent, or taking 
part in a trial evaluating other treatments for their verruca(e).  
 
Recruitment and randomisation of participants 
Participants were recruited between March 2015 and March 2016 from the University 
of Salford Podiatry Clinic. Eligible participants gave written informed consent and 
baseline measures were taken. They were then randomised 1:1 to immediately 
receive needling or callus debridement. A member of the research team telephoned 
the secure, remote randomisation service at the York Trials Unit (YTU), University of 
York, to obtain the allocation. Block randomisation with randomly permuted block 
sizes of 2 and 4 was used. The block size was kept secret from the recruiting 
clinicians.  
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INTERVENTIONS 
Treatments were conducted by two podiatrists proficient in the needling technique 
who received training in trial procedures.  For participants presenting with mosaic or 
multiple plantar verrucae, the largest and thickest lesion (the index verruca) was 
identified.  
 
Control group 
The skin surrounding the index verruca was disinfected and the callus overlying the 
lesion was removed using a surgical blade.  
 
Intervention group: needling procedure  
Intervention participants were treated as described for the control group with the 
addition of the administration of a local anaesthetic (Scandonest 3% plain) via tibial 
nerve block, according to the location of the lesion, prior to callus debridement.  
 
An empty surgical needle (21 gauge) was used to repeatedly puncture through the 
lesion to the subcutaneous tissue to produce point bleeding until there was no more 
resistance, or reactive pressure, from the epidermis. This was done for the whole 
lesion. The total number of punctures varied according to the size of the lesion. In 
the case of large mosaic verrucae, a section of the verruca was needled. This 
follows the practice reported by Longhurst et al8.  
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All participants were asked not to take anti-inflammatory drugs (such as ibuprofen) 
for 48 hours but were permitted to take paracetamol for pain relief.  
 
FOLLOW-UP 
Participants in the needling group attended a review appointment one week after the 
treatment where debridement of any uncomfortable eschar was performed.  
 
Participants completed questionnaires at one day, 12 and 24 weeks and were invited 
for follow-up appointments at 12 and 24 weeks after randomisation. At 12 weeks in 
both groups overlying callus was debrided if the lesion was causing discomfort. At 24 
weeks, if the verruca had not cleared then further, alternative treatments were 
offered.  
All participants received £20 of high street shopping vouchers, divided equally 
between the 12 and 24 week appointments, to offset any incidental expenses 
associated with trial participation.  
 
 
OUTCOME MEASURES 
 
Baseline assessment 
Data on the participant and verruca were collected and a digital photograph of the 
verruca was taken (see Supplementary Materials 1).   
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Primary outcome  
The primary outcome was clearance of the index verruca at 12 weeks after 
randomisation as determined by blinded assessment at site.  The podiatrist was 
asked what treatment they believed the participant had received to assess the 
success of the blinded review.  
 
Secondary outcomes 
Clearance or recurrence of the treated verruca was assessed at 24 weeks. 
Secondary outcomes at 12 and 24 weeks included: time to clearance; clearance of 
all verrucae; number of verrucae; size of the index verruca; pain; and participant 
satisfaction with treatment.  Pain and the use of painkillers 24 hours after treatment 
was collected.  
 
Sample size  
The EVerT2 trial was powered at 80% to detect a difference in clearance rate of the 
index verruca from 30% in the debridement group to 70% in the needling group at 12 
weeks post-randomisation. Allowing for 10% attrition, we required 58 participants to 
be randomised (29 to each treatment group).  
 
Statistical analysis 
Analysis was conducted in Stata v1311 using two-sided statistical tests at the 5% 
significance level for the primary outcome and 1% for secondary outcomes. 
Available case intention to treat was used including all participants in the groups to 
which they were randomised irrespective of whether or not they received their 
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allocated treatment.  Baseline and outcome data, including adverse events, are 
summarised descriptively.  The primary outcome was analysed using a chi-squared 
test.  In a sensitivity analysis, logistic regression was used to adjust the primary 
analysis for duration of the verruca, whether or not the verrucae have been 
previously treated, and type of verruca (mosaic/non-mosaic).  These analyses were 
repeated replacing any missing blinded outcome data with self-reported clearance 
where available.  Clearance of all verrucae at 12 and 24 weeks, and clearance of the 
index verruca at 24 weeks, were analysed via chi-squared tests  &RKHQ¶V NDSSD
was used to measure the agreement of clearance between the participant and the 
blinded assessor at 12 and 24 weeks.  Poisson regression compared the number of 
verrucae at 12 and 24 weeks between the treatment groups, adjusting for the 
number of verrucae at baseline.  Self-reported time to clearance of all verrucae in 
days from randomisation was analysed using Cox proportional hazards regression 
adjusting for duration of verruca, whether or not the verrucae have been previously 
treated and type of verruca.  Pain and size of the index verruca at week 12 and 24 
were analysed via repeated measures covariance pattern models with baseline 
value, treatment group, time and a treatment group-by-time interaction term as fixed 
effects and participant as a random effect.   
 
Total costs per participant were calculated (including all resource use and 
intervention costs) from the perspective of the NHS. A multiple imputation approach 
was taken to account for missing data. 
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RESULTS 
Seventy six individuals were screened and 61 (80.3%) were randomised (Figure 1).  
One ineligible participant (allocated to the needling group) was randomised in error 
as they had a corn and not a verruca.  Therefore, 60 eligible patients were 
randomised; 29 (48.3%) to the needling group and 31 (51.7%) to the debridement 
group.   
 
The majority of participants were female (n=38, 63.3%), and the average age was 38 
years (range 19 to 76) (Table 1).  Participants had had their verruca for a median of 
three years, and most had sought treatment previously (n=47, 78.3%).  The most 
commonly reported reason for seeking treatment was that the verruca was painful 
(n=24, 70.0%).   In general, the two groups were comparable at baseline; however, 
the proportion of women, patients with a mosaic verruca, and patients who had 
sought previous treatment for their verrucae was greater in the needling group than 
in the debridement group, and the average pain experienced was higher.    
 
All participants received their allocated treatment.  Two participants allocated to 
debridement withdrew from the trial: one received debridement but later withdrew as 
they were not happy with the treatment group they had been allocated to and were 
not prepared to wait until after the trial to receive needling; and one missed their 12 
week review and withdrew when invited for their 24 week appointment. 
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At 12 weeks, 53 (88.3%) participants had their index verruca assessed for clearance 
by a blinded assessor (needling n=28, 96.6%; debridement n=25, 80.7%; 
Supplementary materials 2).  Clearance of the index verruca was judged to have 
occurred in 8 (15.1%) participants (needling n=4, 14.3%; debridement n=4, 16.0%, 
difference in percentage -1.7, 95% CI -21.1 to 17.6, p=0.86).  These eight had 
complete clearance of all their verrucae (four participants had one verruca at 
baseline; one each had two, three, four or five).  There was no evidence of a 
difference in the likelihood of clearance between the two groups from the chi-
VTXDUHG WHVW ȋ2=0.03, p=0.86) or the adjusted logistic regression (odds ratio (OR) 
1.10, 95% CI 0.22 to 5.58, p=0.91). Two participants returned a 12 week participant 
questionnaire which included a self-assessment of clearance (both not cleared) but 
GLGQ¶W UHWXUQ IRUDFOLQLFDVVHVVPHQW 7KHUHZDVRQO\DQHJOLJLEOHGLIIHUHQFH LQ WKH
parameter estimates and p-values when the analyses were repeated replacing the 
missing blinded outcome with self-reported clearance (results not presented).  Of the 
eight participants with blinded assessed clearance of all verrucae at 12 weeks, 
seven self-reported that they believed their verrucae had cleared, while one did not.  
7ZR IXUWKHU SDUWLFLSDQWV WKRXJKW WKHLU YHUUXFDH KDG JRQH ZKHQ WKH\ KDGQ¶W  7KH 
level of agreement between self-reported and blinded assessed clearance was high 
(kappa 0.79, p<0.001).  
At week 12, there was no evidence that the age of the verruca is associated with 
clearance (adjusted OR 1.0, 95% CI 0.98 to 1.02, p = 0.74). Also, verrucae that had 
been treated previously were marginally less likely to clear than verrucae that had 
not been treated before, but this difference was not statistically significant (adjusted 
OR 0.8, 95% CI 0.12 to 5.28, p = 0.81). All 8 mosaic verrucae were still present at 
the end of the 12 week period.  
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At week 12, the blinded podiatrists reported that they were unable to tell what 
treatment the participant had received for 48 (90.6%) of the 53 participants assessed 
(needling 24/28 (85.7%); debridement 24/25 (96.0%)).  They believed two needling 
participants had received debridement, but correctly identified the treatment for two 
needling participants and one debridement participant. 
At 24 weeks, 49 (81.7%) participants had their index verruca assessed for clearance 
by a blinded assessor, and 11 (22.5%) were judged to have cleared (needling 5/25 
(20.0%); debridHPHQW   ȋ2=0.18, p=0.68).  All but one of these had 
complete clearance of all verrucae (needling 5/25 (20.0%); debridement 5/24 
 ȋ2=0.01, p=0.94).  Where both self-reported and blinded outcome 
assessments of clearance were available, there was total agreement (kappa 1.00, 
p<0.001).  One participant judged by the blinded assessors to have complete 
clearance did not respond to whether they thought their verrucae had all cleared but 
DQQRWDWHGWKHTXHVWLRQQDLUHZLWK³7KLQNLWPD\KDYHJRQHDs for the last 12 weeks I 
have had no pain.  I found it difficult to see the verruca position as it is in an awkward 
SRVLWLRQ´ There were no reported instances of reoccurrence between weeks 12 and 
24.     
The median number of verrucae at 12 weeks in the needling group was 1.5 (range 0 
to 8) (24 weeks, median 1, range 0 to 8) and in the debridement group was 2 (range 
0 to 19) (24 weeks, median 1, range 0 to 11). There was no evidence of a difference 
in the number of verrucae at 12 weeks (incidence rate ratio (IRR) 0.89, 95% CI 0.67 
to 1.18; p=0.42) or 24 weeks (IRR 0.81, 95% CI 0.50 to 1.31, p=0.39) or in time to 
clearance of all verrucae (hazard ratio (HR) 2.17, 95% CI 0.72 to 6.54; p=0.17) 
between the two groups. 
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Participants in the needling group reported higher levels of pain at baseline and one 
day after treatment than the debridement group, but lower levels at 12 weeks, and at 
24 weeks when the difference was statistically significant (Table 2).  There was a 
small to moderate correlation between pain and verruca size at 12 weeks (r=0.37) 
and 24 weeks (r=0.15). Fifteen (26.3%) of the 57 participants who returned a Day 1 
questionnaire reported using a painkiller after their treatment (all in the needling 
group).  There was no evidence of a difference in the size of the index verruca 
between the two groups at week 12 or 24 weeks (Table 2). 
More participants in the needling group than in the debridement group said that they 
would be willing to have the same treatment again (82.1% compared with 60.0%) 
(Table 3).  Most of the needling group at both 12 and 24 weeks were either happy or 
very happy with their treatment; whereas in the debridement group, a greater 
number were indifferent, unhappy or very unhappy than were happy or very happy.    
There were two non-serious adverse events reported, both unrelated to the trial and 
mild in intensity.  One event was expected (pain, needling participant) and one 
unexpected (GI tract yeast infection, needling participant).  
 
Economic Evaluation 
All patients received at least one treatment visit at the podiatry clinic. The mean 
number of treatment visits was similar between groups (2.14 (SD 0.74) for the 
needling group [n=29] vs 1.96 (SD 0.54) for the debridement group [n=31]). Only one 
participant in each group reported visiting a GP/nurse about their verrucae at the 12 
week assessment.  Accounting for the total number of treatment visits to the podiatry 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
clinics as well as additional GP/nurse visits, the needling intervention costs on 
average £14.33 (95% CI 5.32 to 23.35) more per patient compared to debridement.  
 
Discussion  
This is the largest trial evaluating the clinical and cost effectiveness of the needling 
technique to date.  We found no evidence of a difference in effectiveness between 
needling and callus debridement in terms of clearance rates and verruca size, and 
an increase in cost. However, although the pain 24 hours after treatment was greater 
in the needling group, the pain experienced at 12 and 24 weeks was reduced for this 
group compared to the callus debridement group. At 24 weeks this difference was 
statistically significant.  The needling technique was found to be safe and acceptable 
to participants, and 82% of the needling participants stated that they would be willing 
to have the same treatment again. The needling treatment was associated with 
higher costs per cured patient. Given that there was no difference in the likelihood of 
clearance between the two groups, the needling intervention is dominated hence has 
higher costs for no additional benefit compared to debridement. Needling is thus not 
cost-effective compared to debridement. 
 
Our results for clearance conflict with the findings of the only other RCT of the 
needling procedure by Cunningham et al9. This was a smaller study of 37 
participants and showed a statistically significant difference in clearance rates 
favouring the needling group after 12 weeks, relative to cryotherapy. The clearance 
rate for the needling group was 64.7% (11/17), which is 4.5 times greater than our 
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corresponding rate of 14.3% (4/28). Similarly, Longhurst and Bristow8 reported a 
69% (31/45) resolution of verrucae in a retrospective, case series analysis. However, 
our results are similar to the EVerT trial that reported a 14% cure rate for both 
salicylic acid treatment and cryotherapy12.  
 
Our study followed the same treatment protocols as Longhurst and Cunningham, 
with the exception that participants in our needling group were given one treatment. 
Longhurst and Bristow8 reported a high resolution rate (38/45) after one needling 
treatment. Cunningham et al9 reported a median of 2 treatments, 5 weeks apart and 
a mean (± SD) of 1.61 (0.05) treatments, 5.08 (2.08) weeks apart. Cunningham et al9 
did not report how many verrucae resolved after one or two treatments. The theory 
that verrucae resolve in response to localised tissue damage (which is yet to be 
confirmed) would suggest that this could be achieved after one needling procedure. 
Data on resolution rates is unclear; therefore if two treatments are conducted within 
a few weeks of each other and the verruca resolves it could be possible that the 
response from the first treatment is still occurring when the second treatment is 
administered. We therefore decided that from a trial design perspective, one 
treatment in each group would provide clarity in this regard. We also based our 
decision from an ethical perspective in that if it is likely that the verrucae may resolve 
after one treatment, then it would not be ethical to conduct a second treatment. As 
this is the first large RCT to test the effects of the needling on verrucae, we felt it 
necessary to standardise the interventions between both groups. It is possible that 
multiple treatments are required to stimulate the required immune response and 
promote clearance, and this may help explain the difference in results.  The next 
step in the evaluation of needling treatment would be to test the number of 
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treatments required to achieve verruca resolution. Also, the use of combination 
treatments could be explored, for example the use of home treatments between 
needling treatments.  
 
7KHUHDUHDOVRGLIIHUHQFHVEHWZHHQWKHSRSXODWLRQVLQRXUDQG&XQQLQJKDP¶VWULDOV 
The mean and median ages of the participants in our study (Table 1) are greater 
than those reported by Cunningham et al9 (mean (± SD) = 26.11 (9.99) years and 
median (range) = 22.5 (18 ± 53) years). Cunningham et al9 recruited from the 
university based podiatry clinic only. However, in addition to recruiting from the 
university clinic, we advertised in community areas accessed by the general public, 
such as supermarkets, health centres, day centres, leisure centres and athletics 
clubs. We also placed advertisements in local newspapers and via social media 
accounts. We can therefore accept that we recruited from a wider population than 
the Cunningham study. However, there is a general opinion within the podiatry 
profession (based on peer discussions and not evidence)  that people with tenacious 
verrucae opt for needling after all other treatment options have been exhausted. Our 
data does show that the majority of the participants (78%) had tried other treatments 
before participating in the trial. Cunningham et al9 did not report data on previous 
treatments in their study.  
 
 Though overall the average verruca size at baseline was similar in both trials 
(56.9mm2 versus 52.7mm2), there is an imbalance in verruca size in the Cunningham 
trial and needling participants tended to have much smaller verrucae (mean 
29.1mm2) compared with cryotherapy patients (75.0mm2 ZKLFK ZDVQ¶W DFFRXQWHG
for in the analysis. In addition, our participants tended to have had their verruca for 
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longer than the Cunningham cohort (58 vs 34 months), with an even bigger 
difference seen in the two needling groups (60 vs 29 months). Our data showed now 
association between the age of the verruca and the clearance rate.  
 
Strengths and limitations 
The major strength of this study is that it is of high quality.  The risk of bias has been 
minimised due to the use of adequate randomisation, allocation concealment, 
blinded outcome assessment and intention to treat analysis.  Our study does have 
potential limitations.  It was a single centre study and therefore results may not be 
applicable to patients presenting in GP practices or NHS or private podiatry clinics.  
7KLV WULDO GLGQRW KDYHD WUXHSODFHERRU µQR WUHDWPHQW¶ DUP ,WZDVHQYLVDJHG WKDW
people would volunteer for this study to access the novel treatment needling 
procedure, which is not widely available in the National Health Service (NHS) or 
private podiatry clinics. The risk of losing participants to follow-up would have been 
KLJKLIWKHVHSDUWLFLSDQWVZHUHUDQGRPLVHGLQWRDµQRWUHDWPHQW¶JUoup. Therefore, we 
decided to offer callus debridement (which is currently the treatment provided in 
some NHS podiatry clinics) to maximise participant retention throughout the trial. All 
participants in the control group were offered a free needling treatment at the end of 
the trial if their verruca was VWLOOSUHVHQW7KHXVHRIDµVKDP¶QHHGOLQJWUHDWPHQWIRU
the control group was considered; however, the trial team concluded that it would be 
unethical to administer a local anaesthetic if no treatment was to be given. 
Therefore, it is likely that the clearance we saw was probably due to natural history 
rather than any treatment effects.  
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Summary  
The results of this trial reveal that the verruca needling treatment is no more 
efficacious than callus removal and is more costly. The only significant result was in 
the pain outcomes, which were reduced in the needling group compared to the 
debridement group. The intervention was dominated by usual care in the economic 
evaluation, hence is not cost-effective, compared to usual care. 
 
Acknowledgements The research team would like to thank the independent 
members of the Trial Steering/Data Monitoring and Ethics Committee Professor 
Wesley Vernon OBE and Belinda Longhurst for their advice, oversight of the study 
and reviewing of adverse event data. We would like to thank Sue Royle; Sue Helal 
and Carol Warrender for managing the administration of the participants and the 
blind assessors: Kath Parnell and Angela Wong. 
 
References  
1. Johnson ML, Roberts J. Skin conditions and related need for medical care among 
persons 1-74 years. US Department of Health Education and Welfare Publication 
1978;1660:1-26. 
 
2. Beliaeva TL. The population incidence of warts. Vestnic Dermatologii i 
Venereologii 1990;2:55-8. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
3. Kwok CS, Gibbs S, Bennett C et al. Topical treatments for cutaneous warts. 
Cochrane Database of Systematic Reviews 2012; Issue 9. Art. No.: CD001781. DOI: 
10.1002/14651858.CD001781.pub3. 
4. Sterling JC, Handfield-Jones S, Hudson PM. Guidelines for the management of 
cutaneous warts. Br J Dermatol 2001 Jan;144(1):4-11. 
5. Warts and verrucae. Clinical Knowledge Summaries Jan 2009: 
www.cks.nhs.uk/warts_and_verrucae. 
6. Falknor GW. Needling ² a new technique in verruca therapy. J Am Podiatr Med 
Assoc 1969; 59(2): 51-2. 
7. Liebl H, Kloth LC. Skin cell proliferation stimulated by microneedles. J Am Coll 
Clin Wound Spec 2012; Dec 25;4(1):2-6. doi: 10.1016/j.jccw.2012.11.001. 
eCollection 2012 Mar. 
8. Longhurst B, Bristow I. 7KHWUHDWPHQWRIYHUUXFDHSHGLVXVLQJ)DONQRU¶VQHHGOLQJ
method: a review of 46 cases. J Clin Med 2013; 2(2): 13-21. 
9. Cunningham DJ, Brimage JT, Naraghi RN, et al. Needling versus liquid nitrogen 
cryotherapy for the treatment of pedal warts.  Randomised controlled pilot study. J 
Am Podiatr Med Assoc 2014; 104(4): 394-401. 
10. Hashmi F, Torgerson D, Fairhurst F. et al., EVerT2²needling versus non-
surgical debridement for the treatment of verrucae: study protocol for a single-centre 
randomised controlled trial. BMJ Open 2015; 5(11). 
11. StataCorp., Stata Statistical Software: Release 13. College Station, TX: 
StataCorp LP., 2013. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
13. Cockayne S. Curran M. Denby G. et al., EVerT: cryotherapy versus salicylic acid 
for the treatment of verrucae--a randomised controlled trial. Health Technol Assess. 
2011; 15(32): 1-170. 
 
Figure legend 
Figure 1. CONSORT flow diagram of participants in the EVerT2 trial 
 
Table 1. Baseline characteristics of randomised participants 
 
Characteristic Needling (N=29) 
Debridement 
(N=31) 
Total 
(N=60) 
Age, years 
Mean (SD) 
Median (minimum, maximum) 
N=29 
42.5 (14.2) 
40.4 (23.4, 76.0) 
N=31 
37.1 (12.9) 
36.5 (19.5, 68.7) 
N=60 
39.7 (13.7) 
38.1 (19.5, 76.0) 
Gender, n (%) 
Male 
Female 
 
9 (31.0) 
20 (69.0) 
 
13 (41.9) 
18 (58.1) 
 
22 (36.7) 
38 (63.3) 
No. of verrucae at baseline 
Mean (SD) 
Median (minimum, maximum) 
N=29 
4.0 (3.2) 
3 (1, 11) 
N=31 
4.2 (3.8) 
3 (1, 16) 
N=60 
4.1 (3.5) 
3 (1, 16) 
Duration of verrucae, months 
Mean (SD) 
Median (minimum, maximum) 
N=29 
60.3 (53.5) 
48 (3, 240) 
N=31 
56.2 (62.9) 
36 (6, 312) 
N=60 
58.2 (58.1) 
36 (3, 312) 
Type of verrucae, n (%) 
Mosaic 
Non-mosaic 
 
5 (17.2) 
24 (82.8) 
 
3 (9.7) 
28 (90.3) 
 
8 (13.3) 
52 (86.7) 
Size of index verruca, mm2 
Mean (SD) 
Median (minimum, maximum) 
N=29 
51.9 (78.2) 
22 (2, 356) 
N=31 
61.7 (123.6) 
18 (4, 607) 
N=60 
56.9 (103.4) 
20.5 (2, 607) 
Previous treatment, n (%) 
Yes 
No 
 
25 (86.2) 
4 (13.8) 
 
22 (71.0) 
9 (29.0) 
 
47 (78.3) 
13 (21.7) 
Type of previous treatments, n (%)a 
Over-counter 
Podiatrist treatment 
GP treatment 
Other trial 
Otherb 
 
22 (75.9) 
18 (62.1) 
9 (31.0) 
0 (0.0) 
6 (20.7) 
 
21 (67.7) 
14 (45.2) 
7 (22.6) 
1 (3.2) 
1 (3.2) 
 
43 (71.7) 
32 (53.3) 
16 (26.7) 
1 (1.7) 
7 (11.7) 
Reason for seeking treatment, n (%)a    
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Pain 
Unable to go swimming 
Unable to participate in other sports 
Otherc 
25 (86.2) 
10 (34.5) 
7 (24.1) 
10 (34.5) 
17 (54.8) 
9 (29.0) 
7 (22.6) 
14 (45.2) 
42 (70.0) 
19 (31.7) 
14 (23.3)  
24 (40.0) 
Pain, VAS 0-100 
Mean (SD) 
Median (minimum, maximum) 
N=29 
44.5 (32.3) 
50 (0, 96) 
N=31 
24 (25.5) 
13 (0, 83) 
N=60 
33.9 (30.5)    
28.5 (0, 96) 
Previous verrucae, n (%) 
Yes 
No 
 
16 (64.0) 
9 (36.0) 
 
21 (67.7) 
10 (32.3) 
 
37 (66.1) 
19 (33.9) 
No. of previous verrucae 
Mean (SD) 
Median (minimum, maximum) 
N=16 
4.4 (5.0) 
2 (1, 20) 
N=21 
4.7 (6.5) 
3 (1, 30) 
N=37 
4.5 (5.8) 
2 (1, 30) 
Age at which previous verrucae 
occurred (years) 
Mean (SD) 
Median (minimum, maximum) 
 
N=15 
27.9 (21.0) 
23 (6, 76) 
 
N=22 
18.5 (9.2) 
16.5 (8, 38) 
 
N=37 
22.3 (15.6) 
18 (6, 76) 
a
 More than one category could be checked for each patient 
b
 self-filing/debridement (needling n=3, debridement n=1); duct tape (needling n=2); hospital freeze 
treatment (needling n=1) 
c aesthetics (needling n=5, debridement n=4); concern about passing verruca to others (needling 
n=1, debridement n=5); had it so long/want rid (needling n=1, debridement n=1); prevents from 
walking long distances (needling n=2); invited to take part in EVerT2 trial (debridement n=2); 
verruca getting worse/larger (needling n=1, debridement n=1); wellbeing (debridement n=1) 
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Table 2.  Verruca pain measured on a visual analogue scale, and verruca size (mm2) 
by randomised group and time point 
 
How painful is your 
verruca today?  
0 (no pain)-100 (worst 
possible pain) 
Needling 
(N=29) 
Debridement 
(N=31) 
Adjusted mean 
difference 
(95% CI) 
p-value 
Baseline 
N=29 
44.5 (32.3) 
50 (0, 96) 
N=31 
24.0 (25.5) 
13 (0, 83) 
- 
Day 1 
N=29 
30.3 (25.6) 
21 (0, 89) 
N=28 
8.8 (10.9) 
4 (0, 36) 
- 
Week 12 
N=29 
17.0 (19.6) 
4 (0, 67) 
N=26 
20.4 (24.3) 
6 (0, 78) 
-9.64 
(-20.12, 0.85) 
p=0.07 
Week 24 
  N=24 
10.9 (17.0) 
4 (0, 70) 
N=26 
 15.5 (21.9) 
5 (0, 89) 
-12.54 
(-23.61, -1.46) 
p=0.03 
Size of index verruca, 
mm2 
   
Baseline 
N=29 
51.9 (78.2) 
22 (2, 356) 
N=31 
61.7 (123.6) 
18 (4, 607) 
- 
Week 12 
N=28 
38.3 (69.0) 
11 (0, 337) 
N=24 
50.8 (99.6) 
12.5 (0, 423) 
0.10 
(-20.61, 20.81) 
p=0.99 
Week 24 
N=24 
  46.3 (91.6) 
12.5 (0, 411) 
N=22 
 19.0 (33.7) 
8.5 (0, 145) 
-2.79 
(-34.02, 28.43) 
p=0.86 
 
Data summarised as raw Mean (SD) Median (minimum, maximum) 
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Table 3. Participant satisfaction with treatment by randomised group 
 
 Needling 
(N=29) 
Debridement 
(N=31) 
Total 
(N=60) 
Would you be willing to have the same treatment again? 
Week 12, n (%) 
Yes 
No 
'RQ¶WNQRZ 
 
23 (82.1) 
2 (7.1) 
3 (10.7) 
 
15 (60.0) 
9 (36.0) 
1 (4.0) 
 
38 (71.7) 
11 (20.8) 
4 (7.6) 
How happy are you with your treatment? 
Week 12, n (%) 
Very happy 
Happy 
Neither happy nor unhappy 
Unhappy 
Very unhappy 
 
11 (37.9) 
11 (37.9) 
5 (17.2) 
0 (0.0) 
2 (6.9) 
 
7 (26.9) 
5 (19.2) 
7 (26.9) 
7 (26.9) 
0 (0.0) 
 
18 (32.7) 
16 (29.1) 
12 (21.7) 
7 (12.7) 
2 (3.6) 
Week 24, n (%) 
Very happy 
Happy 
Neither happy nor unhappy 
Unhappy 
Very unhappy 
 
9 (37.5) 
7 (29.2) 
6 (25.0) 
0 (0.0) 
2 (8.3) 
 
7 (26.9) 
4 (15.4) 
10 (38.5) 
5 (19.2) 
0 (0.0) 
 
16 (32.0) 
11 (22.0) 
16 (32.0) 
5 (10.0) 
2 (4.0) 
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Figure 1. CONSORT flow diagram of participants in the EVerT2 trial 
 
 
 
 
 
Assessed for eligibility (n=76) 
Excluded (n=15) 
i Participant had corn, not verruca (n=5)  
i YTU randomisation phone line down 
(n=1)   
i Did not consent (n=9) 
Cancelled/did not attend baseline 
appointment (n=6); Verruca 
resolved/showing signs of resolution 
(n=1); Participant unsure about 
having anaesthetic (n=1); Participant 
moving out of the area (n =1) 
Primary analysis (blinded outcome 
assessment): 
iAnalysed at week 12 (n=28): 
iAnalysed at week 24 (n=25) 
 
Withdrew before Week 12 (n=0) 
 
Week 12 (n=29): 
iAttended the appointment (n=28) 
iCompleted participant questionnaire (n=29) 
 
Withdrew before Week 24 (n=2) 
 
Week 24 (n=27): 
iAttended the appointment (n=25) 
iCompleted participant questionnaire (n=25) 
Allocated to intervention (needling) (n=29) 
i Received allocated intervention (n=29) 
 
Week 1 follow up: 
i Attended appointment (n=13) 
 
Withdrew before Week 24 (n=1) 
 
Week 12 (n=30): 
iAttended the appointment (n=25) 
iCompleted participant questionnaire (n=26) 

Withdrew before Week 24 (n=1) 
 
Week 24 (n=29): 
iAttended the appointment (n=24) 
iCompleted participant questionnaire (n=26) 
Allocated to control (debridement) (n=31) 
i Received allocated intervention (n=31) 
Primary analysis (blinded outcome 
assessment): 
iAnalysed at week 12 (n=25): 
iAnalysed at week 24 (n=24) 
 
Allocation 
Analysis 
Follow-Up 
Randomised (n=61) 
Enrollment 
Randomised in error (n=1) 
i  Participant had corn, not verruca 
